Wall Street analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to announce earnings of ($0.24) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Celldex Therapeutics’ earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.23). Celldex Therapeutics reported earnings per share of ($0.29) during the same quarter last year, which would suggest a positive year-over-year growth rate of 17.2%. The company is expected to issue its next earnings results on Monday, November 6th.

According to Zacks, analysts expect that Celldex Therapeutics will report full-year earnings of ($1.03) per share for the current financial year, with EPS estimates ranging from ($1.07) to ($0.98). For the next financial year, analysts expect that the company will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.12) to ($0.78). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The business had revenue of $3.83 million for the quarter, compared to analyst estimates of $1.21 million. During the same period in the prior year, the business posted ($0.32) earnings per share. Celldex Therapeutics’s revenue was up 175.5% compared to the same quarter last year.

A number of equities research analysts have weighed in on CLDX shares. Aegis reissued a “buy” rating on shares of Celldex Therapeutics in a report on Thursday, June 29th. Zacks Investment Research raised shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research note on Tuesday, July 11th. BidaskClub lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, August 1st. Finally, ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $5.88.

Several large investors have recently bought and sold shares of CLDX. Teachers Advisors LLC boosted its stake in shares of Celldex Therapeutics by 0.9% in the 4th quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock valued at $593,000 after purchasing an additional 1,433 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Celldex Therapeutics by 1.1% during the 1st quarter. Bank of New York Mellon Corp now owns 538,156 shares of the biopharmaceutical company’s stock valued at $1,943,000 after acquiring an additional 5,616 shares during the period. UBS Asset Management Americas Inc. lifted its position in shares of Celldex Therapeutics by 103.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 78,055 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 39,658 shares during the period. Parametric Portfolio Associates LLC lifted its position in shares of Celldex Therapeutics by 2.2% during the 1st quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock valued at $238,000 after acquiring an additional 1,409 shares during the period. Finally, Raymond James Financial Services Advisors Inc. lifted its position in shares of Celldex Therapeutics by 26.2% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 6,000 shares during the period. 56.69% of the stock is currently owned by institutional investors.

Celldex Therapeutics (NASDAQ CLDX) opened at 3.13 on Wednesday. The company has a 50-day moving average of $2.68 and a 200 day moving average of $2.77. Celldex Therapeutics has a one year low of $2.20 and a one year high of $5.02. The firm’s market capitalization is $401.71 million.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per Share” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/zacks-analysts-anticipate-celldex-therapeutics-inc-cldx-will-announce-earnings-of-0-24-per-share.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.